1. This list relates to pyridine [1,5-a] pyridine and pyridine [1,5-a] pyridine derivatives, which are LSD1 inhibitors used in the treatment of cancer and other diseases. 1. Claim 1: a formula compound (1),or one of its pharmaceutically acceptable salts, characterized in that: X is N or CRX； ring A is C₆₋₁₀ aryl or 5-10 membered heteroaryl comprising carbon and 1, 2, 3, or 4 heteroatoms selected from N, O, and S, wherein said C₆₋₁₀ aryl and 5-10 membered heteroaryl they are optionally substituted with 1, 2, 3, or 4 substituents independently selected from RA； ring B is aryl C₆₋₁₀；a. A heteromorphism consisting of 5-10 members, including carbon and 1, 2, 3 or 4 heteromorphic atoms selected from n, O, y, s；or 4-10 membered heterocycloalkyl comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O, and S； where said aryl C₆₋₁₀,5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl,and 4-10 membered heterocycloalkyl are optionally substituted with 1, 2, 3, or 4 substituents independently selected from RB； R¹ is halo, C₁₋₆ alkyl,C₂₋₆ alkenyl,1. C 83228331 asphalt；C₁₋₆ haloalkyl,Cy1,CN ORSRᵃ¹,C (O) RC (O) NR RC (O) OROC (O) ROC (O) NR RNR RNo. 7580；； 1 C (o) r7495；； 1No. 7580； 1 C (o) or7491； 1,NR C (O) NR RC (3DNR) RC (3DNR) NR RNR C (3DNR) NR RNR S (O) RNR S (O) RNR S (O) NR RS (O) RS (O) NR RS (O) Ry S (O) NR Rwhere said C₁₋₆ alkyl,C₂₋₆ alkenyl,and C₂₋₆ alkynyl are optionally substituted with 1, 2, or 3 substituents independently selected from Cy¹,halo CN ORSRᵃ¹,C (O) RC (O) NR RC (O) OROC (O) ROC (O) NR RNR RNo. 7580；； 1 C (o) r7495；； 1No. 7580； 1 C (o) or7491； 1,NR C (O) NR RC (3DNR) RC (3DNR) NR RNR C (3DNR) NR RNR S (O) RNR S (O) RNR S (O) NR RS (O) RS (O) NR RS (o) 8322；； r74955；； 1 and S (o) 8322；； nr7580808；； 1 r7496；； 1R³ is H, halo, C₁₋₆ alkyl,C₂₋₆ alkenyl,1. C 83228331 asphalt；C₁₋₆ haloalkyl,ScionCN ORSRᵃ³,C (O) RC (O) NRᶜ³Rᵈ³,C (O) OROC (O) ROC (O) NR RNR RNR C (O) RNo. 7580； 3 C (o) or7491； 3,No. 7580； + C (o) 7580； + r749696； + 3C (= No. 749773； 3) r74955； 3C
